Seattle Genetics Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Seattle Genetics (SGEN) PT Raised to $79 at Needham & Company
July 27, 2018 12:22 PM EDTNeedham & Company raised its price target on Seattle Genetics (NASDAQ: SGEN) to $79.00 (from $74.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Seattle handily beat Street consensus with 2Q:18 ADCETRIS sales of $122M, higher than our $109M and similar Street... More
Seattle Genetics (SGEN) PT Raised to $64 at Cowen
July 27, 2018 11:29 AM EDTCowen raised its price target on Seattle Genetics (NASDAQ: SGEN) to $64.00 (from $54.00) while maintaining a Outperform rating
Analyst Boris Peaker noted strength was driven by strong adoption in the frontline HL by community docs, although he said the recent stock run-up factors in this stronger uptake.
... MoreSeattle Genetics (SGEN) PT Raised to $81 at SunTrust Robinson Humphrey
July 27, 2018 8:05 AM EDTSunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $81.00 (from $80.00) while maintaining a Buy rating.
Analyst Yatin Suneja commented, "Adcetris surprised with another stronger than expected 2Q18 sales (+14%/$14.8MM vs. consensus), on robust uptake in frontline (1L) cHL.... More
Seattle Genetics (SGEN) Reports Q2 EPS of $0.47, Revenues Beat; Offers FY18 Outlook
July 26, 2018 4:05 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q2 EPS of $0.47, versus ($0.39) reported last year. Revenue for the quarter came in at $170.17 million versus the consensus estimate of $141.07 million.
Our ADCETRIS sales growth in the first full quarter following FDA approval in frontline Stage III or IV classical Hodgkin lymphoma demonstrates a strong reception from the oncology... More
